Objective. To provide a comprehensive overview of the potential for morphine to lead to angiogenesis and metastasis.
Introduction
Treatments for the management of cancer have improved greatly over the past decade. People are living increasingly longer times with advanced cancers. An estimated 64% of these patients suffer from severe, debilitating cancer pain that requires aggressive treatment to improve quality of life [1] . The treatment of choice for this severe pain is often morphine, which can lead to tolerance and addiction. Individuals classified as opioid addicts have been reported to have an increased incidence of infectious disease as well as a reduction in T lymphocyte number and function [2] [3] [4] . Of greater concern, there have been an increasing number of studies over the past 20 years examining the association of opioid use with potential increases in cancer recurrence. Several studies since the 1990s have indicated that morphine may have immunosuppressant properties, which may cause cancer growth. "First, do no harm"-a fundamental principle in the practice of medicine-has many providers evaluating the use of opioids and their potential cancer risks. This review attempts to give an updated clarification of how opioid analgesia (more specifically morphine) may promote tumor growth and metastasis in in vitro models.
Methods
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed when conducting and reporting this review and metaanalysis.
Literature Search
A review of the current literature was performed with a systematic literature search performed in the PubMed V C 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com (1966 ( to July 2015 and Cochrane Library (1987 to July 2015) electronic databases. The search terms "opioid," "tumor," "chronic opioid use," "metastasis," "morphine," and "angiogenesis" were combined in searches through both databases. Once duplicates were removed, this yielded 84 abstracts for initial review. The full text of the article was obtained if the title or abstract discussed opioid use resulting in angiogenesis or metastasis. Articles that were not written in English or did not discuss in vitro opioid use were excluded. Specifically, to be included, articles had to discuss a potential mechanism of action associated with angiogenesis or metastasis. A total of 28 articles were obtained and read in their entirety, of which 16 were excluded because they did not discuss in vitro models or expound on a mechanism of action. Twelve articles met the inclusion criteria for this review of the current literature. In addition to the electronic search, experts in the field were contacted for further article suggestions. If articles were missing or if the author team knew of pertinent literature that did not include specific details for inclusion in the review, the corresponding authors were contacted for the relevant information. References from all the included articles were reviewed to ensure that all articles meeting inclusion criteria were included.
Assessment of Study Quality
The Cochrane Risk of Bias was used to measure the methodological quality of the included studies. The Cochrane Risk of Bias System has a list of seven items that assess the internal validity of the study and are scored by allocating a þ, -, or ? to each criteria that is met. The more þ signs, the lower the risk of bias. Each study was independently assessed. All results are summarized in Table 1 .
Data Extraction
The 12 included articles were reviewed completely, and the primary etiological theories were extracted to be included in the summary tables.
Opioid Overview
All opioid analgesics mimic endogenous endorphins; they stimulate opioid receptors l, k, and d in the central and peripheral nervous systems. The exact response depends on which receptor the opioid binds to and the opioid's relative affinity to the receptor. The l-opioid receptor (MOR) is the main target for opiates. In addition to mediating the main clinical effect of opioids, which is analgesia, it mediates adverse effects, such as addiction, respiratory depression, and constipation [5].
Opioids Are Immunosuppressants
Many studies have indicated that opioids are immunosuppressive. The immune system is critical in preventing tumor formation and metastasis. Tumor cells express non-self antigens and can be destroyed via the cytotoxic action of cytokines. As a result, mice lacking the appropriate immunosurveillance have been found to be more susceptible to tumorigenesis [6, 7] . An intact immune system plays a key role in fighting tumor development and growth [7, 8] . Chronic administration of opioids, in particular morphine, inhibits immune system responses: antibody production, natural killer (NK) cell activity, cytokine expression, blood lymphocyte proliferation responses, and phagocytic activity [9-11].
Opioid receptors are also found in the cells of the immune system, e.g., macrophages, polymorphonuclear leukocytes, T-lymphocytes, splenocytes, macrophagelike cells, and T-cells [11] . Opioids added to these cell lines in vitro alter protein expression and may reduce chemotaxis and phagocytosis by macrophage-reduced B-cell proliferation and antibody formation [12, 13] . In contrast, it appears that morphine has minimal effects on in vitro NK cell activity. Endogenous opioids lead to increased NK cell activity, which can be inhibited by naloxone [14] . Naloxone competes with 17 b-estradiol for binding to the estrogen receptor and acts as an antagonist on the receptor, with obvious therapeutic implications in estrogen-dependent tumors [15] . Morphine is thought to act on regulatory T-cells via vascular endothelial growth factor (VEGF) receptor 2. Morphine may impact regulatory T-cells by altering the function of immune cells or cytokines such as TGF-b or IL-2 [16] .
Opioids modulate the immune response via central and peripheral mechanisms [17] . The hypothalamicpituitary-adrenal axis is potentiated with chronic opioid exposure, leading to synthesis of glucocorticoids, which are immunosuppressive once synthesized. In contrast, the more immediate effects of opioids include its interaction with noradrenaline, which reduces immunocompetence [17, 18] . Further, the sympathetic nervous system may play a role in suppressing lymphocyte proliferation and NK cell activity [17] . Some animal studies have demonstrated that morphine immunosuppression is absent without the l-receptor [19] . On the other hand, other animal studies have concluded that withdrawal from morphine induced marked immunosuppression [20] .
Morphine and Inflammation Are Closely Related
Inflammation is part of a complex biological response to harmful stimuli, including pathogens, damaged cells, and irritants [21] . These same risk factors that may cause inflammation were found to induce tumor development. Inflammation affects immune response to tumors. Tumor development is often accompanied by an inflammatory response, which enhances its development [7] . Cytokines can affect immune cells and lead to the release of endogenous opioids at sites of inflammation [22] [23] [24] . K-and l-receptors may play opposite roles in receptor activation. The K-opioid receptor induces an anti-inflammatory response, while the lreceptor produces a pro-inflammatory response [25] . Because morphine binds the l-receptor more tightly, Does Opioid Use Cause Angiogenesis and Metastasis? the pro-inflammatory response is often favored. At the same time, morphine has been shown to prevent inflammation-induced angiogenesis in vivo [26] . This conflicting information can make it challenging to elucidate the exact role of morphine.
Morphine Modulates Angiogenesis
Previous studies have shown the potential role of morphine in angiogenesis. Endothelial cells express opioid receptors, so they increase the intracellular calcium concentration and nitric oxide (NO) production when opiates are present [13, [27] [28] [29] . In addition to increasing vascular permeability, NO regulates endothelial cell proliferation, migration, and protease release, all key roles in angiogenesis. Moreover, morphine may cause activation of inflammation via activation of the toll-like receptor 4 (TLR4) through binding of the TLR4-associated protein myeloid differentiation protein-2 on central nervous system cells [15] . Morphine also activates mitogenactivated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and pro-survival Akt in cultured endothelial cells [28] . In vitro, morphine induces endothelial cell proliferation and migration via transactivation of growth factor receptors, in particular VEGF receptor 2 and platelet-derived growth factor receptor b (PDGFR b), that play a very important role in migration and survival of these cells [30, 31] . Methylnaltrexone can attenuate the endothelial barrier disruption produced by morphine in vitro and reduce lipopolysaccharideinduced vascular hyperpermeability in murine lung in vivo [31] . Endothelial cell disruption, migration, and proliferation play a major role in angiogenesis [31] . In a non-endothelial cell system, morphine was shown to transactivate fibroblast growth factor (FGF) receptor 1, which plays a major role in angiogenesis [32] . While some of morphine's pro-angiogenic effects are not reversed by naloxone, morphine-induced tumor growth can be reversed by the cyclooxygenase-2 inhibitor celocoxib [33] .
One of the proposed mechanisms by which the VEGF pathway increases endothelial cell migration involves intercellular adhesion molecule 1 (ICAM-1). When VEGF stimulates endothelial cells, it increases ICAM-1 expression. Further, ICAM-1 blocking antibody decreases VEGF-induced endothelial migration, and ICAM-1 deficient endothelial cells exhibit reduced endothelial NO synthase activation, NO bioavailability, and endothelial cell migration [34, 35] . VEGF is highly prevalent in the tumor microenvironment and is often thought of as the angiogenic switch. ICAM-1 increases endothelial cell migration and mediates the recruitment of endothelial progenitor cells, which play a key role in angiogenesis [36] . In addition, endothelial cells exposed to l-agonists upregulate ICAM-1 [37] . Morphine activation of VEGF may result in increased endothelial cell motility mediated by NO and ICAM-1. Downstream from the VEGF receptor, VEGF stimulates a proto-oncogene called sarcoma (Src). Morphine also stimulates Src. Zhang et al. reported that Src phosphorylation can act as a switch to alter MOR signaling from an inhibitory to a stimulatory signal [38] . It has been suggested that morphine may affect the same pathway at multiple different points.
Others have argued that morphine may also inhibit tumor angiogenesis by suppressing VEGF signaling via the kappa-opioid receptor (KOR), which is one of the targets of morphine [39, 40] . This is analogous to the anti-cancer drug bevacizumab. KOR knockout mice grafted with Lewis lung carcinoma or B16 melanoma showed increased proliferation and enhanced angiogenesis compared with wild type mice [39] . In addition, repeated intraperitoneal injection of TRK820 significantly reduced tumor angiogenesis and tumor growth [41] . These findings may indicate that KOR agonists play an important role in tumor angiogenesis, and thus suppress angiogenesis in the short term [2, 40] .
Opioids can transactivate growth factor receptors relevant to cancer growth: morphine-induced phosphorylation of the epidermal growth factor receptor (EGFR) occurs via opioid receptors, and the co-activation of EGFR by opioid receptors can be antagonized by naloxone. Opioid receptors also transactivate PDGFR b [4]. This may impair vascular pericyte coverage [41] .
It is theorized that there may be crosstalk between tumor cells and non-cancerous cells [15] . Further, there is occasionally upregulation of l-receptors in tumor cell lines and samples. Morphine has been shown to downregulate basic FGF production in human macrophages [15] . Additionally, in a small sample of 34 human lung cancer and normal adjacent lung tissue samples, MOR expression was increased significantly in samples from patients with lung cancer compared with controls [43] . In animal models, overexpression of MOR promotes tumor growth and metastasis [43] . This may support the idea that MOR plays a role in tumor progression.
One animal study proposed that morphine does not affect tumor onset but promotes development of established tumors with increased MOR expression [43] . Because morphine stimulates mast cell degranulation [3, 44] , which then release Substance P [45] , morphine use can affect angiogenesis in these pathways as well. Mast cells have been shown to promote the growth of pancreatic ductal adenocarcinoma in mice [46] , while substance P has been shown to directly influence cancer progression by transactivating human epidermal growth factor receptor 2 in human breast cancer cells [47, 48] .
Morphine may also suppress tumor angiogenesis through an HIF-1alpha/p38MAPK pathway [49] . Morphine was found to reduce blood vessel density, branching, and length when compared with placebo [49] . However, morphine's effect was abolished in mice co-administered the opioid receptor antagonist naltrexone and in MOR knockout mice [49] . This inhibitory effect could be modulated via the suppression of the hypoxia-induced mitochondrial p38 MAPK pathway [34] . [49] [50] [51] . Other studies described a reciprocal increase in peripheral blood leukocytes that was observed at the time of plug or sponge removal in morphine-treated mice [52] . Furthermore, morphine was found to indirectly inhibit agenesis via reduced inflammation [43, 53] .
Human Studies
While most of the studies done in this area were done on animals, a few studies were performed on human subjects. One smaller study showed that patients receiving intrathecal opioids exhibited increased survival (54%) compared with systemic opioids (37%) [54] . There may be a multitude of different reasons for the etiology of the difference in survival; one theory might be that because the tumor wasn't exposed to systemic opioids, cancer progression was attenuated.
Other studies have shown that certain polymorphisms of the MOR may be linked to increased survival in breast cancer. The A118G polymorphism results in decreased responsiveness to l-opioids. In a study performed on 2,039 women, 5% of African American and 24% of European American women had one or two copies of the G allele. Of the women with the A/A genotype and invasive cancer, 17% died of the disease versus 8% of the women with the G allele, and the difference was statistically significant [55] . A retrospective analysis of 600 patients with stage IV prostate cancer showed that increased MOR expression and greater opioid requirement are associated with shorter progression-free survival and overall survival [55] . These same findings were confirmed in non-small cell lung carcinoma [56] .
Conclusion
Opioids, particularly morphine, are the most widely used medications to manage severe cancer-associated pain. It is uncertain whether there is a clear relationship between opioid use and angiogenesis or metastasis, although the potential does exist. Therefore, pain management physicians and oncologists have questioned the use of opioids in cancer patients and must evaluate the use of appropriate alternatives. Alternatives to systemic opioid administration may include anticonvulsants, antidepressants, regional pain blocks, neuromodulation, and intrathecal drug delivery. Despite retrospective analysis of alternatives to opioid analgesia and animal models, it is not clear whether altered tumor cell proliferation and invasion, inflammation, angiogenesis, and immune response will result in significant harm to the patient. Studies in animal models and in vivo cell models do not always translate into human disease. As a result, further research, including prospective randomized controlled trials, is necessary to fully understand these pathways.
